The Oil Search Limited (ASX: OSH) share price is outperforming today even as it suffered a big drop in quarterly revenue.

The Oil Search share price jumped 1.8% to $3.06 in morning trade when the S&P/ASX 200 Index (Index:^AXJO) gained 1.1%.

The rally in Oil Search puts it well ahead of its peers as well. The Beach Energy Ltd (ASX: BPT) share price fell 0.9%, the Santos Ltd (ASX: STO) share price added 0.8% and the Woodside Petroleum Limited (ASX: WPL) share price improved 1%.

Every dog gets its day

Oil Search’s stronger run today stands in contrast to its poor performance. The stock is the worst performer in the group as it crashed 54% over the past year. Shares in Santos and Beach shed around 23% while Woodside lost 40% over the same period.

The big slump in the crude oil price during the COVID-19 market turmoil is dragging on the energy sector, but Oil Search is hit harder due to governance and political challenges relating to its PNG project.

But these issues are brushed aside when Oil Search released its quarterly production update on Tuesday.

Strong production run

The group’s latest quarterly operated oil production jumped 14% over the previous quarter to its highest since the PNG earthquake in 2018.

While total production in the June quarter dipped 1% compared to the March quarter, the half-year figure of 14.66 million barrels of oil equivalent (mmboe) is 4% above 1HCY19.

However, while production is up, revenue in the three months to end June tumbled 26% to US$266.2 million compared to the first quarter of calendar year 2020.

On track to hit target

But the drop in revenue was expected given the well documented plunge in oil and gas prices, while the production figures were probably ahead of what many had feared.

“Despite the challenging COVID operating conditions and restrictions on personnel movement, our safety record for the quarter was excellent across all areas and our PNG oilfield operations performed above expectations,” said Oil Search’s managing director Keiran Wulff.

“Combined with continued strong production from the ExxonMobil-operated PNG LNG Project, Oil Search is on track to achieve its production targets in 2020.”

Other positives for Oil Search

The group also successfully completed its two-well Alaskan exploration program with new oil discoveries conveniently close to existing and proposed infrastructure.

Oil Search also looks well placed to survive the unpredictable trading environment as it raised around US$700 million in capital in May.

Is Oil Search share price a buy?

While the positive quarterly update gives the embattled energy company much needed relief, I don’t think it will be enough to trigger a re-rating in the stock.

There are still too many unanswered questions relating to Oil Search’s alleged role in a bribery scandal in PNG.

This means Oil Search will likely continue to trade at a discount to its peers until the governance issues are resolved.

More reading

• What the latest economic data could mean for ASX 200 shares
• ASX 200 jumps 1.15%: BHP Q4 update, tech shares rocket higher
• Mesoblast share price climbs 9% on FDA meeting
• What you need to know about Downer’s share price, $400m cap raise and acquisition
• 3 tips for investing in ASX 200 shares for beginners

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The worst performing ASX 200 oil stock is finally catching a break today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/32CBiO5

Data. That’s what many experienced investors are focused on amid all the noise on the S&P/ASX 200 Index (ASX: XJO) this week.

There are a lot of updates that are set to be released by the Australian Government in coming days. That kicks off today, with the Reserve Bank of Australia (RBA)’s meeting minutes. Reserve Bank Governor Philip Lowe will give a speech, while the government will give an update on JobKeeper and JobSeeker.

Investors are also eyeing a fiscal and economic update due on Thursday, which will give a more detailed look at those programs and a budget update.

So, what do all these different announcements and datasets mean for ASX 200 shares in 2020? Here’s a closer look at 3 major ASX sectors and how they could be impacted.

ASX 200 retail shares

I think a big one here is the JobKeeper updates today and Thursday. According to news reports, the payment programs will be extended beyond September, but with a change in eligibility.

Aussie retailers have been struggling in 2020 with coronavirus restrictions reducing in-store sales. I think extended government support would be good news for retailers. More government support means more money in the economy and higher employment. Another helpful impact could be more spending money in the pockets of everyday Aussies.

That has helped ASX retail shares like JB Hi-Fi Limited (ASX: JBH) and Super Retail Group Ltd (ASX: SUL) climb higher in 2020. Online sales channels have been the key as demand for particular items has soared. 

There’s also preliminary retail sales data for June that will be released by the Australian Bureau of Statistics (ABS) on Wednesday. That will give investors a good gauge of how sales are tracking and what to expect from the August earnings season.

ASX bank shares

Governor Philip Lowe’s speech is set to focus on COVID-19, the labour market and the government’s balance sheet.

I think ASX bank share investors will be watching the speech and RBA meeting minutes closely.

Major banks like Commonwealth Bank of Australia (ASX: CBA) are a key part of the government’s COVID-19 response plan. The banks are such a crucial part of the Aussie economy that I think we will see strong share price moves this week.

Support for employment would surely be welcomed by the Aussie banks and the economy as a whole. Any extension of JobKeeper would also reassure investors that the risk of mass defaults in September/October is low.

Fiscal and monetary stimulus is currently propping up the economy. An extension of that, and the form that extension takes, will impact on the banks’ ability to lend with confidence and maintain asset quality in 2020.

ASX REITs

I think the preliminary retail sales data on Wednesday will be the big one for retail REITs like Scentre Group (ASX: SCG). The JobKeeper and JobSeeker update today and Thursday will also be worth watching.

Looking further ahead, we’re also expecting an update on building permits from the ABS next Thursday. That is one to watch for investors in ASX 200 diversified REITs like Mirvac Group (ASX: MGR). The new data could provide an indication of new industry activity, competition and potential trends for pricing and supply in the short to medium-term.

More reading

• The worst performing ASX 200 oil stock is finally catching a break today
• ASX 200 jumps 1.15%: BHP Q4 update, tech shares rocket higher
• Mesoblast share price climbs 9% on FDA meeting
• What you need to know about Downer’s share price, $400m cap raise and acquisition
• 3 tips for investing in ASX 200 shares for beginners

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Super Retail Group Limited. The Motley Fool Australia has recommended Scentre Group. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post What the latest economic data could mean for ASX 200 shares appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2WHorq7

In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to record a very strong gain. At the time of writing the benchmark index is up a sizeable 1.35% to 6,082.2 points. This is thanks largely to strong gains in the tech sector.

Four shares that are climbing more than most today are listed below. Here’s why they are racing higher:

The Afterpay Ltd (ASX: APT) share price is up almost 8% to $74.89. Investors have been buying Afterpay and other tech shares on Tuesday after their U.S. counterparts stormed higher on the technology-focused Nasdaq index overnight. At the time of writing the S&P/ASX 200 Information Technology index is up an impressive 5.5%.

The Ecofibre Ltd (ASX: EOF) share price has jumped 10% to $2.49. Investors have been buying the hemp products company’s shares after the release of its profit guidance on Monday. Ecofibre is expecting to report a net profit after tax of ~$12.5 million in FY 2020. This will be more than double what it achieved in FY 2019. Its strong position in the U.S. market has driven the impressive profit growth.

The Mesoblast limited (ASX: MSB) share price has climbed almost 8% higher to $3.61. This follows the announcement of a review date for its remestemcel-L treatment by the U.S. FDA. The review will assess data supporting Mesoblast’s application for approval for remestemcel-L in the treatment of steroid-refractory acute graft versus host disease in children.

The Zip Co Ltd (ASX: Z1P) share price is up almost 9% to $6.57. As well as getting a lift from the rampant buying in the tech sector, Zip’s shares were given a boost from a broker note out of Ord Minnett this morning. Its analysts have put an accumulate rating and $6.45 price target on the buy now pay later provider’s shares.

More reading

• Mesoblast share price climbs 9% on FDA meeting
• 3 tips for investing in ASX 200 shares for beginners
• Why I would buy Afterpay and these exciting ASX tech shares
• Top fund manager names favourite ASX growth shares
• Why the BlueScope share price is outperforming today

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of ZIPCOLTD FPO. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Afterpay, Ecofibre, Mesoblast, & Zip Co shares are racing higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3eOpVFp

At lunch on Tuesday S&P/ASX 200 Index (ASX: XJO) is on course to record a very strong gain. The benchmark index is currently up 1.15% to 6,071.1 points.

Here’s what has been happening on the market today:

Big four banks push higher.

The big four banks are all pushing higher on Tuesday. The best performer in the group is the Commonwealth Bank of Australia (ASX: CBA) share price with a gain of 1.5%. Investors have been buying the banking giant’s shares despite analysts at Goldman Sachs rating them as a sell this morning.

Tech shares storm higher.

It has been a fantastic day for Australia’s leading tech shares. The likes of Altium Limited (ASX: ALU) and Nearmap Ltd (ASX: NEA) are storming notably higher. This has driven the S&P/ASX 200 Information Technology index 5.5% higher at lunch. The catalyst for this was a very positive night of trade on Wall Street’s technology-focused Nasdaq index. It jumped 2.5% thanks to strong gains by the likes of Amazon, Apple, Microsoft, and Google parent, Alphabet. Amazon was the star of the show with a gain of almost 8%.

BHP Q4 update

The BHP Group Ltd (ASX: BHP) share price is trading sideways on Tuesday following the release of its fourth quarter and full year update. BHP had a solid 12 months with production guidance met for iron ore, metallurgical coal, and operated copper and energy coal assets. Iron ore production was the highlight of FY 2020 with 248 Mt produced. BHP commanded an average realised price of US$77.36 a tonne for the steel making ingredient. This was up 16% year on year.

Best and worst ASX 200 shares.

The best performer on the ASX 200 on Tuesday has been the Nearmap share price with an impressive 10% gain. This follows strong buying in the tech sector today. The worst performer has been the Alumina Limited (ASX: AWC) share price with a 4% decline. This may be down to profit taking after some very strong gains last week.

More reading

• The worst performing ASX 200 oil stock is finally catching a break today
• What the latest economic data could mean for ASX 200 shares
• Mesoblast share price climbs 9% on FDA meeting
• Why AGL Energy, Alumina, BlueScope, & BWX shares are dropping lower
• What you need to know about Downer’s share price, $400m cap raise and acquisition

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Altium and Nearmap Ltd. The Motley Fool Australia has recommended Nearmap Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post ASX 200 jumps 1.15%: BHP Q4 update, tech shares rocket higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2WFtmIc

The Mesoblast limited (ASX: MSB) share price has jumped 8.9% this morning after the healthcare company announced a review date for its remestemcel-L treatment has been granted by the FDA. The review will assess data supporting Mesoblast’s application for approval for remestemcel-L in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children. 

SR-aGVHD is a potentially life threatening complication from bone marrow transplants for blood cancer. There are currently no FDA approved treatments in the United States for children under the age of 12 with SR-aGVHD. An advisory committee will review the data on 13 August and make a recommendation regarding approval to the FDA. 

What is remestemcel-L?

Remestemcel-L is a therapy utilising mesenchymal stem cells derived from bone marrow. It is administered via a series of intravenous infusions. The treatment is believed to counteract inflammatory processes and enable recruitment of naturally occurring anti-inflammatory cells to involved tissues. Remestemcel-L has gained significant publicity recently due to its use in the treatment of COVID-19 patients. 

Remestemcel-L is currently undergoing phase 3 trials to assess its use in treating adult COVID-19 patients with acute respiratory distress syndrome. The product is also available in the US for compassionate use for child COVID-19 patients with cardiovascular and other complications of multisystem inflammatory syndrome. 

How is the Mesoblast share price performing? 

During the nine months to 31 March 2020, Mesoblast reported revenues of US$31.5 million. This was a 113% increase on the prior corresponding period when US$14.8 million in revenue was reported. Loss after tax reduced to US$45.3 million for the first nine months of FY20, compared to a loss of US$69.1 million for the first nine months of FY19. 

The Mesoblast share price has gained 146% over the last year and 233% from its March low. Encouraging results from clinical trials of remestemcel-L have pushed the Mesoblast share price higher, as has its use in the treatment of coronavirus. Mesoblast’s increased share price saw it join the S&P/ASX 200 (ASX: XJO) in the most recent quarterly rebalance. 

What’s next for Mesoblast?

Mesoblast had cash on hand of $60.1 million at 31 March 2020. An additional $138 million of capital was raised in May which will be used to scale up manufacturing of remestemcel-L for the treatment of COVID-19 patients. The company is now well positioned to pursue this new imperative with clinical trials underway. 

More reading

• The worst performing ASX 200 oil stock is finally catching a break today
• What the latest economic data could mean for ASX 200 shares
• Why Afterpay, Ecofibre, Mesoblast, & Zip Co shares are racing higher
• ASX 200 jumps 1.15%: BHP Q4 update, tech shares rocket higher
• What you need to know about Downer’s share price, $400m cap raise and acquisition

Motley Fool contributor Kate O’Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Mesoblast share price climbs 9% on FDA meeting appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2ZJCldo

The WAM Global Limited (ASX: WGB) share price is up around 3% after announcing a larger-than expected FY20 final dividend for investors.

Overview of WAM Global

WAM Global is a listed investment company (LIC). It’s operated by Wilson Asset Management. The job of a LIC is to invest in other shares on your behalf. As the name may suggest, WAM Global invests in global shares. It’s meant to be the international version of WAM Capital Limited (ASX: WAM). It provides geographic and currency diversification compared to the domestic WAM LICs.

One of the benefits of LICs is that they can make investment returns from capital gains as well as receiving investment income from shares. LICs can then pay out some of those investment returns as steady dividends or retain the profit for more growth.

WAM Global looks for international shares where there’s a catalyst that would cause the share price to rise. It’s particularly looking for what it describes as ‘undervalued international growth companies’.

For shareholders it wants to provide a stream of fully franked dividends, provide capital growth over the medium-to-long term and preserve capital. As WAM Global’s investments grow in value, hopefully the WAM Global share price will rise as well.

FY20 dividend

The board of WAM Global decided to declare a fully franked final dividend of 4 cents per share, bringing the FY20 final dividend to 7 cents per share. This is a 250% increase on FY19’s total dividend and a 100% increase on the final FY19 dividend.

To pay future dividends WAM Global needs a profit reserve to pay from. WAM Global said that it had a profit reserve of 24 cents per share as at 30 June 220, which is 3.4 years of dividend coverage. WAM Global said it wants to pay a growing stream of fully franked dividends.

FY20 investment performance

The WAM Global share price and dividends are influenced by the investment performance of the LIC.

Before fees, expenses and taxes, the WAM Global investment portfolio increased by 3.1% during FY20, it outperformed the MSCI World SMID (small/mid) Cap Index in Australian dollar terms by 5%. However, it unperformed the MSCI World Index (AUD) which rose by 4.8%, it was driven by large cap tech companies which performed strongly during COVID-19 such as Amazon.

What shares does WAM Global own?

WAM Global revealed some of shares it owned at the end of June 2020.

Its biggest 10 positions included: Nomad Foods, Tencent, Lowe’s, Dollar General, Thermo Fisher Scientific, Kobe Bussan, Microsoft, Aon, AutoZone and Hasbro.

The next biggest 10 holdings were: Intuit, CME, Intercontinental Exchange, CDW, HelloFresh, Logitech, Edwards Lifesciences, Electronic Arts, Fidelity National Information Services and Arista Networks.

This is a diversified group of shares that should be able to perform well regardless of what the global economy does in regards to COVID-19.

Is the WAM Global share price a buy?

At the current WAM Global share price it’s trading at a 14% discount to the net tangible asset (NTA) despite today’s rise. I think that’s an attractive discount. The LIC that is well managed and has the potential to keep outperforming the MSCI small and medium cap index.

With the bigger than expected final FY20 dividend, WAM Global now offers an impressive dividend yield. Using an annual dividend payment of 7 cents per share, it offers a grossed-up dividend yield of 5.1%. If WAM Global pays another 4 cents per share dividend in six months then the forward grossed-up dividend yield could be 5.8%.

The management fees are certainly a drag on the net performance of the LIC, but if your focus is dividend income then I think this is a good time to buy WAM Global shares at an attractive NTA discount with a growing dividend.

More reading

• 3 blue chip ASX 200 dividend shares to buy in the next market correction
• 2 ASX shares I would buy for growth and income
• 3 ASX dividend shares growing their payouts fast
• ASX income stalwart WAM Capital announces 8.2% dividend
• Safe ASX 200 dividend shares to buy today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post WAM Global grows FY20 dividend by 250%, share price up appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2WFuMlS

The ASX is home to a dynamic and fast growing tech market. Here we look at 2 ASX tech shares that I believe could be worthy additions to your share portfolio: Bravura Solutions Ltd (ASX: BVS) and Megaport Ltd (ASX: MP1).

Bravura

Bravura is a locally based fintech company. It provides mission-critical enterprise software solutions to both the wealth management and funds administration industry. Since it was founded in 2015, Bravura has seen impressive revenue growth. In FY19, Bravura’s overall revenue increased strongly by 16% to $257.7. million and its earnings before interest, tax, depreciation and amortisation were up by 27%. 

The Bravura share price was hit hard during the early phase of the coronavirus pandemic. It has seen a partial recovery since then, and has been trading in the $4–$5 zone since late April. Over the next few months, I see potential for further share price gains from pre-COVID 19 levels as Bravura has not reported any major decline in demand during the pandemic.

Over the longer term, I believe Bravura is well positioned for continued strong revenue and profitability growth, driven by a growing product set and increased demand for wealth management software solutions globally.

Megaport

Megaport provides a ‘network as a service’ offering to enterprises. It is also commonly referred to as an elastic interconnection service. This enables enterprises to increase or decrease their fixed broadband bandwidth. The service is enabled via a network of cloud providers, data centre operators, and network service providers.

Megaport continues to grow its customer base across Asia Pacific, Europe and North America. This ASX tech share reported a whopping 70% increase in revenue to $25.9 million in the first half of FY 2020.

The Megaport share price has also performed strongly recently, increasing by more than 100% over the past year.

I believe that Megaport is well placed to continue its growth story over the next few years, driven by the continued rise of cloud computing and the need for rapid connectivity. 

Foolish takeaway

Both Bravura and Megaport are 2 of my top ASX tech share picks right now. Both have strong entrenched market positions in their respective tech niches. Both tech companies also continue to grow their international presence, which in my opinion is likely to lead to strong revenue growth in the years to come.

More reading

• Buy and hold these mid cap ASX shares for strong potential returns
• 5 of the worst performing ASX shares from last week
• ASX 200 Weekly Wrap: Blue chip shares pull ASX 200 back over 6,000 points
• Want to beat the market? Try these 3 ASX growth shares
• These were the worst performing ASX 200 shares last week

Phil Harpur owns shares of MEGAPORT FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of MEGAPORT FPO. The Motley Fool Australia owns shares of and has recommended Bravura Solutions Ltd. The Motley Fool Australia has recommended MEGAPORT FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 2 top ASX tech shares to buy right now appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30Cqc9s

It has been a very positive day for the S&P/ASX 200 Index (ASX: XJO). In late morning trade the benchmark index is up almost 1% to 6,059.2 points.

Four shares that have failed to follow the market higher today are listed below. Here’s why they are dropping lower:

The AGL Energy Limited (ASX: AGL) share price is down 2% to $17.10. As the energy company is regarded as a safe haven asset, investors may be selling its shares and rotating back into risk-on assets due to improving investor sentiment. In addition to this, earlier this month Macquarie downgraded AGL’s shares to an underperform rating with a $15.91 price target.

The Alumina Limited (ASX: AWC) share price is down 4% to $1.71. Investors may be taking profit after some strong gains this month following its quarterly update. One broker that still thinks the Alumina share price can go higher is Morgan Stanley. On Monday it retained its overweight rating and price target of $2.00.

The BlueScope Steel Limited (ASX: BSL) share price is down almost 1.5% to $11.43. This could have been triggered by another note out of Morgan Stanley on Monday. It slapped an underweight rating and $10.00 price target on this steel producer’s shares. This follows the recent release of its guidance for FY 2020.

The BWX Ltd (ASX: BWX) share price has fallen 4% to $4.10. This may be a case of profit taking from investors after some very strong gains by the personal care products company’s shares this month. Prior to today, BWX’s shares were up 22% since the start of the month. This follows the release of its unaudited full year result which revealed strong sales and earnings growth. The company is also currently raising funds to enhance its manufacturing capability and future-proof its supply chain.

More reading

• Why the BlueScope share price is outperforming today
• 5 top performing ASX 200 shares from last week
• ASX 200 down 0.5%: Sydney Airport and South32 updates, HUB24 delivers record Q4
• ASX 200 Weekly Wrap: Blue chip shares pull ASX 200 back over 6,000 points
• These were the best performing ASX 200 shares last week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended BWX Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why AGL Energy, Alumina, BlueScope, & BWX shares are dropping lower appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2ZMmCKD

The Immuron Limited (ASX: IMC) share price is up by 89.80% to 46 cents per share this morning on news that Immuron’s product IMM-124E has neutralising activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.

This follows on from another positive announcement yesterday that the U.S. Food and Drug Administration (FDA) provided guidance about the development pathway for Immuron’s new oral therapeutic drugs.

What sent Immuron’s share price skyrocketing?

The Immuron share price has shot higher in early trade following news that IMM-124E, which is used in the manufacture of Immuron’s flagship drugs Travelan and Protectyn, demonstrates antiviral activity against COVID-19 in laboratory testing.

Trevelan is Immuron’s only drug that currently generates revenue and is predominantly used to reduce the risk of traveller’s diarrhoea and minor gastro-intestinal disorders. It is licensed in Australia, Canada and sold as a dietary supplement in the US.

The company reports that the cytopathic effect inhibition cell-based assay was established and performed by 360 biolabs, a Melbourne-based contract research organisation. All 4 of the tests performed saw inhibition of Covid-19 of at least 50%. Higher concentrations of IMM-124E stemmed the virus replication by up to 90%. None of the tests demonstrated any cell toxicity.

Commenting on the early results, Immuron CEO Dr Jerry Kanellos stated: 

The preliminary data set we have generated potentially offers a new oral therapeutic approach to target and directly inhibit the virus in the Gastrointestinal tract and warrants further evaluation to identify the inhibitory substances in our products. The company has filed a provisional patent application in respect of the findings.

What now for Immuron?

Immuron is an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut-mediated pathogens such as campylobacteriosis and E. coli (ETEC).

After languishing around the 12 cent mark over the past year, the Immuron share price has seen a stark reversal in fortunes, jumping 275% on 9 June alone, in response to news of briefing documentation being submitted to the FDA. The Immuron share price is up 253% year to date, and currently sits at 46 cents per share.

More reading

• Immuron share price shoots 6% higher after receiving FDA guidance for new drug

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Immuron share price shoots 90% higher on potential COVID-19 treatment news appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/32DtonJ